anti-NKG2D-ligand CAR T-cell therapy (Cellular Biomedicine)

N/A

Report date: 2025/03/20 15:45:54

Base Information

Drug Nameanti-NKG2D-ligand CAR T-cell therapy (Cellular Biomedicine)

Drug Alias NameNKG2D-derived CAR T-cell therapy (Cellular Biomedicine)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionNKG2D ligands modulators

TargetsNKG2D ligands

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesAbelZeta Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbelZeta Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A